Journal of Clinical Biochemistry and Nutrition
Online ISSN : 1880-5086
Print ISSN : 0912-0009
ISSN-L : 0912-0009
Original Articles
Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
Yoshitsugi ItoMakoto SasakiYasushi FunakiNaotaka OgasawaraMari MizunoAkihito IidaShinya IzawaRyuta MasuiYoshihiro KondoYasuhiro TamuraKenichiro YanamotoHisatsugu NodaAtsushi TanabeNoriko OkaniwaYoshiharu YamaguchiKunio Kasugai
Author information
JOURNAL FREE ACCESS

2013 Volume 53 Issue 1 Pages 55-59

Details
Abstract
Permeation of the small intestinal mucosa is a key mechanism in the induction of enteropathy. We investigated the effect of rebamipide in healthy subjects with diclofenac-induced small intestinal damage and permeability. In this crossover study, each treatment period was 1 week with a 4-week washout period. Diclofenac (75 mg/day) and omeprazole (20 mg/day) plus rebamipide (300 mg/day) or placebo were administered. Capsule endoscopy and a sugar permeability test were performed on days 1 and 7 in each period. Ten healthy subjects were enrolled. Small intestinal injuries were observed on day 7 in 6 of 10 subjects in both groups. Urinary excretion of administered lactulose increased from 0.30% to 0.50% of the initial dose during the first treatment period in the placebo group, and from 0.13% to 0.33% in the rebamipide group. Despite recovery from small-intestinal mucosal damage, the increased permeability in both groups resulted in sustained high levels of lactulose (0.50% to 1.06% in the placebo group and 0.33% to 1.12% in the rebamipide group) through the 4-week washout period. Diclofenac administration induced enteropathy and hyperpermeability of the small intestine. The sustained hyperpermeability during the washout period may indicate the presence of invisible fragility.
Content from these authors
© 2013 JCBN
Previous article Next article
feedback
Top